Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy.
We present an evidence-based overview of primary prevention of sudden cardiac death. Several recent studies have provided important data regarding pharmacologic and device-based therapy for patients with conditions that confer high risk for sudden death. A rational approach to these therapies, with emphasis on implanted cardiovertor defibrillators, is discussed.
Klein
George J
GJ
Division of Cardiology, University of Western Ontario, London, Ontario, Canada. gklein@uwo.ca
Krahn
Andrew D
AD
Skanes
Allan C
AC
Yee
Raymond
R
Gula
Lorne J
LJ
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D016757:Death, Sudden, Cardiac / Q000453:epidemiology* / Q000517:prevention & control*; D004554:Electric Countershock / Q000706:statistics & numerical data*; D019317:Evidence-Based Medicine; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D015995:Prevalence; D011320:Primary Health Care / Q000706:statistics & numerical data; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents